Baptiste Gaborieau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Baptiste Gaborieau has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Damien Ricard
AP-HP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation, Colombes, France; Université Paris Cité, UMR1137 IAME, INSERM, Paris, France
10 shared publications - Laurent Debarbieux
Institut Pasteur
9 shared publications - Chantal Weissfuss
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Care, Berlin, Germany
5 shared publications - Geraldine Nouailles
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Care, Berlin, Germany
5 shared publications - Magdalena Bürkle
Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
5 shared publications - Aude Bernheim
Molecular Diversity of Microbes Laboratory, Institut Pasteur, Université Paris-Cité, CNRS UMR3525, Paris, France
4 shared publications
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Déterminants génétiques de la résistance bactérienne aux bactériophages au cours d'une phagothérapie pulmonaire expérimentale
La résistance aux antibiotiques est une menace mondiale pour la santé publique. Malgré les plans de lutte contre l'antibiorésistance, la multirésistance ne cesse de progresser et expose à un risque accru d'impasse thérapeutique en médecine humaine. Elle est devenue particulièrement préoccupante au cours des infections associées aux soins à Escherichia coli, et notamment dans le contexte de la réanimation au cours des pneumonies acquises sous ventilation mécanique. Parmi les alternatives à l'antibiothérapie, l'utilisation thérapeutique de bactériophage est une solution prometteuse et efficace. Cependant, la phagothérapie est mise au défi par l'émergence rapide de bactéries développant une résistance aux bactériophages. Les mécanismes de résistance ont pour la plupart été identifiés et étudiés in vitro, tandis que la résistance émergente au cours des traitements de phagothérapie reste mal caractérisée. Ce travail se propose de caractériser sur le plan génomique la résistance bactérienne aux bactériophages au cours d'un traitement par phage dans un modèle murin expérimental de pneumonie aigu à E. coli. Dans un travail de pharmacométrie et de modélisation de la phagothérapie pulmonaire, nous avons mis en évidence plusieurs facteurs clés pour le succès du traitement par phage. En couplant un outil d'imagerie in vivo pour suivre longitudinalement les animaux dans le temps avec un modèle mathématique, nous avons caractérisé l'interaction entre phages et bactéries lors du traitement, par une dose unique du phage virulent 536_P1, d'une pneumonie murine induite par la souche E. coli 536. Le modèle a mis en évidence plusieurs paramètres clés pour l'efficacité thérapeutique des phages, et surtout, souligne le rôle critique d'une population bactérienne réfractaire, comprenant les bactéries inaccessibles aux phages et/ou les bactéries résistantes aux phages. Nous avons ensuite caractérisé sur le plan phénotypique et génomique les clones résistants au phage dans ce même modèle, en comparaison de ceux émergeant au cours d'une culture in vitro en milieu liquide. Nous avons identifié une convergence mutationnelle des deux conditions vers des gènes impliqués dans la biosynthèse d'un composant de la paroi cellulaire (LPS ou capsule K15). Alors que les mutations liées au LPS étaient associées à une perte quasi-totale de virulence, les mutants de la capsule K15 restaient aussi virulents que la souche sauvage. Enfin, certains clones résistants aux phages devenaient sensibles à d'autres phages incapables d'infecter la souche sauvage, suggérant que les cocktails de phages n'ont pas nécessairement besoin d'inclure uniquement des phages, tous capables d'infecter la souche pathogène ciblée. Enfin, nous avons réalisé une caractérisation phénotypique et génomique d'une banque représentative d'une centaine de phages, isolés sur plus de 35 souches d'E. coli, et testée sur une collection de 370 souches représentatives du genre Escherichia. Les bactéries étaient globalement résistantes à l'infection par les phages. Le spectre d'hôte des phages était corrélé à leur proximité génomique. La phylogénie bactérienne ne semblait pas être le déterminant principal du spectre d'hôte au niveau intra-espèce, suggérant un rôle des systèmes de défense et du transfert horizontal de gènes. Ces travaux soulignent l'importance de la résistance bactérienne au bactériophage au cours d'une phagothérapie comme facteur critique d'échec thérapeutique, notamment selon le mécanisme de résistance. Une grande attention devrait être accordée à ces mécanismes au cours de la constitution de cocktails thérapeutiques de phages, notamment chez des patients présentant d'autres facteurs d'échec du traitement (immunodépression, biofilm).
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Déterminants génétiques de la résistance bactérienne aux bactériophages au cours d'une phagothérapie pulmonaire expérimentale
La résistance aux antibiotiques est une menace mondiale pour la santé publique. Malgré les plans de lutte contre l'antibiorésistance, la multirésistance ne cesse de progresser et expose à un risque accru d'impasse thérapeutique en médecine humaine. Elle est devenue particulièrement préoccupante au cours des infections associées aux soins à Escherichia coli, et notamment dans le contexte de la réanimation au cours des pneumonies acquises sous ventilation mécanique. Parmi les alternatives à l'antibiothérapie, l'utilisation thérapeutique de bactériophage est une solution prometteuse et efficace. Cependant, la phagothérapie est mise au défi par l'émergence rapide de bactéries développant une résistance aux bactériophages. Les mécanismes de résistance ont pour la plupart été identifiés et étudiés in vitro, tandis que la résistance émergente au cours des traitements de phagothérapie reste mal caractérisée. Ce travail se propose de caractériser sur le plan génomique la résistance bactérienne aux bactériophages au cours d'un traitement par phage dans un modèle murin expérimental de pneumonie aigu à E. coli. Dans un travail de pharmacométrie et de modélisation de la phagothérapie pulmonaire, nous avons mis en évidence plusieurs facteurs clés pour le succès du traitement par phage. En couplant un outil d'imagerie in vivo pour suivre longitudinalement les animaux dans le temps avec un modèle mathématique, nous avons caractérisé l'interaction entre phages et bactéries lors du traitement, par une dose unique du phage virulent 536_P1, d'une pneumonie murine induite par la souche E. coli 536. Le modèle a mis en évidence plusieurs paramètres clés pour l'efficacité thérapeutique des phages, et surtout, souligne le rôle critique d'une population bactérienne réfractaire, comprenant les bactéries inaccessibles aux phages et/ou les bactéries résistantes aux phages. Nous avons ensuite caractérisé sur le plan phénotypique et génomique les clones résistants au phage dans ce même modèle, en comparaison de ceux émergeant au cours d'une culture in vitro en milieu liquide. Nous avons identifié une convergence mutationnelle des deux conditions vers des gènes impliqués dans la biosynthèse d'un composant de la paroi cellulaire (LPS ou capsule K15). Alors que les mutations liées au LPS étaient associées à une perte quasi-totale de virulence, les mutants de la capsule K15 restaient aussi virulents que la souche sauvage. Enfin, certains clones résistants aux phages devenaient sensibles à d'autres phages incapables d'infecter la souche sauvage, suggérant que les cocktails de phages n'ont pas nécessairement besoin d'inclure uniquement des phages, tous capables d'infecter la souche pathogène ciblée. Enfin, nous avons réalisé une caractérisation phénotypique et génomique d'une banque représentative d'une centaine de phages, isolés sur plus de 35 souches d'E. coli, et testée sur une collection de 370 souches représentatives du genre Escherichia. Les bactéries étaient globalement résistantes à l'infection par les phages. Le spectre d'hôte des phages était corrélé à leur proximité génomique. La phylogénie bactérienne ne semblait pas être le déterminant principal du spectre d'hôte au niveau intra-espèce, suggérant un rôle des systèmes de défense et du transfert horizontal de gènes. Ces travaux soulignent l'importance de la résistance bactérienne au bactériophage au cours d'une phagothérapie comme facteur critique d'échec thérapeutique, notamment selon le mécanisme de résistance. Une grande attention devrait être accordée à ces mécanismes au cours de la constitution de cocktails thérapeutiques de phages, notamment chez des patients présentant d'autres facteurs d'échec du traitement (immunodépression, biofilm).
- Open Access
Environment and physiology shape antiphage system expression
Bacteria and archaea encode on average ten antiphage systems. Quorum sensing, cellular, or transcription factors can regulate specific systems (CRISPR-Cas, CBASS). Yet, a systematic assessment of antiphage systems expression patterns is lacking. Here, we combine publicly available RNA-seq data from 14 different species with an original RNA-seq dataset of 15 Escherichia coli strains across six environmental conditions and two growth stages. Using this data, we explore the transcription patterns of 236 antiphage systems from 81 types. Defense system expression is variable along environmental, physiological, as well as spatial gradients, and can correlate with cellular physiology and mobile genetic element activity. We identify antiphage systems as cohesive but complex transcriptional units, find coordinated expression of defense islands possibly underpinned by local regulators, and demonstrate the functional relevance of differential expression in native systems. Together, these results suggest that environmental and physiological factors regulate prokaryotic immunity and may prime bacteria for infection.
Open AccessEnvironment and physiology shape antiphage system expression
Bacteria and archaea encode on average ten antiphage systems. Quorum sensing, cellular, or transcription factors can regulate specific systems (CRISPR-Cas, CBASS). Yet, a systematic assessment of antiphage systems expression patterns is lacking. Here, we combine publicly available RNA-seq data from 14 different species with an original RNA-seq dataset of 15 Escherichia coli strains across six environmental conditions and two growth stages. Using this data, we explore the transcription patterns of 236 antiphage systems from 81 types. Defense system expression is variable along environmental, physiological, as well as spatial gradients, and can correlate with cellular physiology and mobile genetic element activity. We identify antiphage systems as cohesive but complex transcriptional units, find coordinated expression of defense islands possibly underpinned by local regulators, and demonstrate the functional relevance of differential expression in native systems. Together, these results suggest that environmental and physiological factors regulate prokaryotic immunity and may prime bacteria for infection.
- 4 September 2025
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 380 (1934) , 20240082
Why do bacteria accumulate antiphage defence systems?
While it is well established that bacterial genomes encode multiple and diverse antiphage systems, the reasons for their co-occurrence and their heterogeneous distribution remain debated. This review examines why bacteria accumulate antiphage systems and how this influences phage–bacteria interactions, particularly in the context of phage therapy. Two main hypotheses may explain this phenomenon: (i) the pan-immunity hypothesis, which suggests that defence system accumulation provides protection against phage predation at the community level, and (ii) mobile genetic element (MGE) competition, where defence systems primarily protect intra-bacterial MGEs against other ones rather than the bacterial host itself. The ecological context also influences the distribution of antiphage systems, with defencee accumulation shaping phage–bacteria interactions in diverse communities but playing a lesser role at the species level, potentially explaining why multiple defences do not strongly limit phage host range in therapeutic settings. Finally, we address the challenges in understanding the drivers shaping the distribution of defence systems across bacterial genomes (expressions, costs, etc.) and their implications for elucidating the ecological role of defence systems and optimizing phage therapy strategies. This article is part of the discussion meeting issue ‘The ecology and evolution of bacterial immune systems’.
- 4 September 2025
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 380 (1934) , 20240082
Why do bacteria accumulate antiphage defence systems?
While it is well established that bacterial genomes encode multiple and diverse antiphage systems, the reasons for their co-occurrence and their heterogeneous distribution remain debated. This review examines why bacteria accumulate antiphage systems and how this influences phage–bacteria interactions, particularly in the context of phage therapy. Two main hypotheses may explain this phenomenon: (i) the pan-immunity hypothesis, which suggests that defence system accumulation provides protection against phage predation at the community level, and (ii) mobile genetic element (MGE) competition, where defence systems primarily protect intra-bacterial MGEs against other ones rather than the bacterial host itself. The ecological context also influences the distribution of antiphage systems, with defencee accumulation shaping phage–bacteria interactions in diverse communities but playing a lesser role at the species level, potentially explaining why multiple defences do not strongly limit phage host range in therapeutic settings. Finally, we address the challenges in understanding the drivers shaping the distribution of defence systems across bacterial genomes (expressions, costs, etc.) and their implications for elucidating the ecological role of defence systems and optimizing phage therapy strategies. This article is part of the discussion meeting issue ‘The ecology and evolution of bacterial immune systems’.
- Open Access
- 15 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Adjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we use a murine model of Pseudomonas-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or phages alone. Combined treatment in murine VAP results in faster clinical improvement and prevents lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduces the minimum effective concentration of meropenem and prevents resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.
- 15 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessAdjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we use a murine model of Pseudomonas-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or phages alone. Combined treatment in murine VAP results in faster clinical improvement and prevents lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduces the minimum effective concentration of meropenem and prevents resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.
- Open Access
- 2 January 2025
- Published by Oxford University Press (OUP) in The ISME Journal
- Vol. 19 (1)
Phage–phage competition and biofilms affect interactions between two virulent bacteriophages and Pseudomonas aeruginosa
Virulent bacteriophages (or phages) are viruses that specifically infect and lyse a bacterial host. When multiple phages co-infect a bacterial host, the extent of lysis and dynamics of bacteria–phage and phage–phage interactions are expected to vary. The objective of this study is to identify the factors influencing the interaction of two virulent phages with different Pseudomonas aeruginosa growth states (planktonic, an infected epithelial cell line, and biofilm) by measuring the bacterial time-kill and individual phage replication kinetics. A single administration of phages effectively reduced P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, but phage-resistant variants subsequently emerged. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and the meropenem antibiotic. In contrast, adherent biofilms showed tolerance to phage and/or meropenem, suggesting a spatio-temporal variation in the phage–bacterial interaction. The kinetics of adsorption of each phage to P. aeruginosa during single or co-administration were comparable. However, the phage with the shorter lysis time depleted bacterial resources early and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage. The extent and strength of this phage–phage competition and genetic loci conferring phage resistance are, however, P. aeruginosa genotype-dependent. Nevertheless, adding phages sequentially resulted in their unimpeded replication with no significant increase in bacterial host lysis. These results highlight the interrelatedness of phage–phage competition, phage resistance, and specific bacterial growth state (planktonic/biofilm) in shaping the interplay among P. aeruginosa and virulent phages.
- 2 January 2025
- Published by Oxford University Press (OUP) in The ISME Journal
- Vol. 19 (1)
Open AccessPhage–phage competition and biofilms affect interactions between two virulent bacteriophages and Pseudomonas aeruginosa
Virulent bacteriophages (or phages) are viruses that specifically infect and lyse a bacterial host. When multiple phages co-infect a bacterial host, the extent of lysis and dynamics of bacteria–phage and phage–phage interactions are expected to vary. The objective of this study is to identify the factors influencing the interaction of two virulent phages with different Pseudomonas aeruginosa growth states (planktonic, an infected epithelial cell line, and biofilm) by measuring the bacterial time-kill and individual phage replication kinetics. A single administration of phages effectively reduced P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, but phage-resistant variants subsequently emerged. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and the meropenem antibiotic. In contrast, adherent biofilms showed tolerance to phage and/or meropenem, suggesting a spatio-temporal variation in the phage–bacterial interaction. The kinetics of adsorption of each phage to P. aeruginosa during single or co-administration were comparable. However, the phage with the shorter lysis time depleted bacterial resources early and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage. The extent and strength of this phage–phage competition and genetic loci conferring phage resistance are, however, P. aeruginosa genotype-dependent. Nevertheless, adding phages sequentially resulted in their unimpeded replication with no significant increase in bacterial host lysis. These results highlight the interrelatedness of phage–phage competition, phage resistance, and specific bacterial growth state (planktonic/biofilm) in shaping the interplay among P. aeruginosa and virulent phages.
- Top Cited Papers
- 31 October 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (11) , 2847-2861
Prediction of strain level phage–host interactions across the Escherichia genus using only genomic information
Predicting bacteriophage infection of specific bacterial strains promises advancements in phage therapy and microbial ecology. Whether the dynamics of well-established phage–host model systems generalize to the wide diversity of microbes is currently unknown. Here we show that we could accurately predict the outcomes of phage–bacteria interactions at the strain level in natural isolates from the genus Escherichia using only genomic data (area under the receiver operating characteristic curve (AUROC) of 86%). We experimentally established a dataset of interactions between 403 diverse Escherichia strains and 96 phages. Most interactions are explained by adsorption factors as opposed to antiphage systems which play a marginal role. We trained predictive algorithms and pinpoint poorly predicted interactions to direct future research efforts. Finally, we established a pipeline to recommend tailored phage cocktails, demonstrating efficiency on 100 pathogenic E. coli isolates. This work provides quantitative insights into phage–host specificity and supports the use of predictive algorithms in phage therapy.
- 31 October 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (11) , 2847-2861
Top Cited PapersPrediction of strain level phage–host interactions across the Escherichia genus using only genomic information
Predicting bacteriophage infection of specific bacterial strains promises advancements in phage therapy and microbial ecology. Whether the dynamics of well-established phage–host model systems generalize to the wide diversity of microbes is currently unknown. Here we show that we could accurately predict the outcomes of phage–bacteria interactions at the strain level in natural isolates from the genus Escherichia using only genomic data (area under the receiver operating characteristic curve (AUROC) of 86%). We experimentally established a dataset of interactions between 403 diverse Escherichia strains and 96 phages. Most interactions are explained by adsorption factors as opposed to antiphage systems which play a marginal role. We trained predictive algorithms and pinpoint poorly predicted interactions to direct future research efforts. Finally, we established a pipeline to recommend tailored phage cocktails, demonstrating efficiency on 100 pathogenic E. coli isolates. This work provides quantitative insights into phage–host specificity and supports the use of predictive algorithms in phage therapy.
- Open Access
- 22 October 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (10) , e0111324
Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy
Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and in vivo (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification in vivo could be predicted from in vitro assays. Phage-resistant clones exhibited a wide range of fitness according to in vitro tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively. IMPORTANCE: This study isolated more than 50 phage-resistant mutants from both in vitro and in vivo conditions, exposing an extra-intestinal pathogenic Escherichia coli strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified in vitro ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an in vivo virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.
- 22 October 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (10) , e0111324
Open AccessVariable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy
Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and in vivo (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification in vivo could be predicted from in vitro assays. Phage-resistant clones exhibited a wide range of fitness according to in vitro tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively. IMPORTANCE: This study isolated more than 50 phage-resistant mutants from both in vitro and in vivo conditions, exposing an extra-intestinal pathogenic Escherichia coli strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified in vitro ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an in vivo virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.
- Open Access
- 26 September 2024
- Published by Springer Nature in Research Square
Adjunctive phage therapy improves antibiotic treatment of Ventilator-Associated-Pneumonia with Pseudomonas aeruginosa
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we used a murine model of Pseudomonas aeruginosa-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or the phage cocktail alone. Combined treatment led to faster recovery of VAP-mice and prevented lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduced the minimum effective concentration of meropenem and prevented resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.
- 26 September 2024
- Published by Springer Nature in Research Square
Open AccessAdjunctive phage therapy improves antibiotic treatment of Ventilator-Associated-Pneumonia with Pseudomonas aeruginosa
Bacterial multidrug resistance poses an urgent challenge for the treatment of critically ill patients developing ventilator-associated pneumonia (VAP). Phage therapy, a potential alternative when conventional antibiotics fail, has been unsuccessful in first clinical trials when used alone. Whether combining antibiotics with phages may enhance effectiveness remains to be tested in experimental models. Here, we used a murine model of Pseudomonas aeruginosa-induced VAP to compare the efficacy of adjunctive phage cocktail for antibiotic therapy to either meropenem or the phage cocktail alone. Combined treatment led to faster recovery of VAP-mice and prevented lung epithelial cell damage. Using human primary epithelial cells to dissect these synergistic effects, we find that adjunctive phage therapy reduced the minimum effective concentration of meropenem and prevented resistance development against both treatments. These findings suggest adjunctive phage therapy represents a promising treatment for MDR-induced VAP, enhancing the effectiveness of both antibiotics and phages while reducing adverse effects.
- Open Access
Phage-phage competition and biofilms reduce the efficacy of a combination of two virulent bacteriophages against Pseudomonas aeruginosa
Combined use of virulent bacteriophages (phages) and antibiotics reduces the severity of difficult-to-treat Pseudomonas aeruginosa infections in many patients. In vitro methods that attempt to reproduce more than one physiological state of the pathogens can provide a valuable assessment of antibacterials like phages. Here, by measuring bacterial killing kinetics and individual replication in different growth conditions, including biofilms and a human lung epithelial cell line, we elucidated factors influencing the efficacy of two virulent phages against P. aeruginosa PAO1. A single administration of phages effectively reduced the P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, however, the emergence of phage-resistant variants occurred subsequently. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and meropenem. In contrast, surface-attached biofilms exhibited tolerance to phage and/or meropenem, suggesting a spatiotemporal variation in the antibacterial effect. Moreover, the phage with the shorter lysis time lysed P. aeruginosa more rapidly and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage of the combination. The sequential addition of phages resulted in their unimpeded replication with no increase in bacteriolytic activity. These findings highlight biofilm developmental stages, phage-phage competition, and phage resistance as factors restricting the in vitro efficacy of a two-phage combination. Our findings provide a framework for selecting and optimizing phage combinations for enhanced efficacy against P. aeruginosa , a metabolically flexible pathogen that undergoes specific adaptation within the infected lung.
Open AccessPhage-phage competition and biofilms reduce the efficacy of a combination of two virulent bacteriophages against Pseudomonas aeruginosa
Combined use of virulent bacteriophages (phages) and antibiotics reduces the severity of difficult-to-treat Pseudomonas aeruginosa infections in many patients. In vitro methods that attempt to reproduce more than one physiological state of the pathogens can provide a valuable assessment of antibacterials like phages. Here, by measuring bacterial killing kinetics and individual replication in different growth conditions, including biofilms and a human lung epithelial cell line, we elucidated factors influencing the efficacy of two virulent phages against P. aeruginosa PAO1. A single administration of phages effectively reduced the P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, however, the emergence of phage-resistant variants occurred subsequently. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and meropenem. In contrast, surface-attached biofilms exhibited tolerance to phage and/or meropenem, suggesting a spatiotemporal variation in the antibacterial effect. Moreover, the phage with the shorter lysis time lysed P. aeruginosa more rapidly and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage of the combination. The sequential addition of phages resulted in their unimpeded replication with no increase in bacteriolytic activity. These findings highlight biofilm developmental stages, phage-phage competition, and phage resistance as factors restricting the in vitro efficacy of a two-phage combination. Our findings provide a framework for selecting and optimizing phage combinations for enhanced efficacy against P. aeruginosa , a metabolically flexible pathogen that undergoes specific adaptation within the infected lung.
- Open Access
Predicting phage-bacteria interactions at the strain level from genomes
Predicting how phages can selectively infect specific bacterial strains holds promise for developing novel approaches to combat bacterial infections and better understanding microbial ecology. Experimental studies on phage-bacteria interactions have been mostly focusing on a few model organisms to understand the molecular mechanisms which makes a particular bacterial strain susceptible to a given phage. However, both bacteria and phages are extremely diverse in natural contexts. How well the concepts learned from well-established experimental models generalize to a broad diversity of what is encountered in the wild is currently unknown. Recent advances in genomics allow to identify traits involved in phage-host specificity, implying that these traits could be utilized for the prediction of such interactions. Here, we show that we could predict outcomes of most phage-bacteria interactions at the strain level in Escherichia natural isolates based solely on genomic data. First, we established a dataset of experimental outcomes of phage-bacteria interactions of 403 natural, phylogenetically diverse, Escherichia strains to 96 bacteriophages matched with fully sequenced and genomically characterized strains and phages. To predict these interactions, we set out to define genomic traits with predictive power. We show that most interactions in our dataset can be explained by adsorption factors as opposed to antiphage systems which play a marginal role. We then trained predictive algorithms to pinpoint which interactions could be accurately predicted and where future research should focus on. Finally, we show the application of such predictions by establishing a pipeline to recommend tailored phage cocktails to target pathogenic strains from their genomes only and show higher efficiency of tailored cocktails on a collection of 100 pathogenic E. coli isolates. Altogether, this work provides quantitative insights into understanding phage–host specificity at the strain level and paves the way for the use of predictive algorithms in phage therapy.
Open AccessPredicting phage-bacteria interactions at the strain level from genomes
Predicting how phages can selectively infect specific bacterial strains holds promise for developing novel approaches to combat bacterial infections and better understanding microbial ecology. Experimental studies on phage-bacteria interactions have been mostly focusing on a few model organisms to understand the molecular mechanisms which makes a particular bacterial strain susceptible to a given phage. However, both bacteria and phages are extremely diverse in natural contexts. How well the concepts learned from well-established experimental models generalize to a broad diversity of what is encountered in the wild is currently unknown. Recent advances in genomics allow to identify traits involved in phage-host specificity, implying that these traits could be utilized for the prediction of such interactions. Here, we show that we could predict outcomes of most phage-bacteria interactions at the strain level in Escherichia natural isolates based solely on genomic data. First, we established a dataset of experimental outcomes of phage-bacteria interactions of 403 natural, phylogenetically diverse, Escherichia strains to 96 bacteriophages matched with fully sequenced and genomically characterized strains and phages. To predict these interactions, we set out to define genomic traits with predictive power. We show that most interactions in our dataset can be explained by adsorption factors as opposed to antiphage systems which play a marginal role. We then trained predictive algorithms to pinpoint which interactions could be accurately predicted and where future research should focus on. Finally, we show the application of such predictions by establishing a pipeline to recommend tailored phage cocktails to target pathogenic strains from their genomes only and show higher efficiency of tailored cocktails on a collection of 100 pathogenic E. coli isolates. Altogether, this work provides quantitative insights into understanding phage–host specificity at the strain level and paves the way for the use of predictive algorithms in phage therapy.